1. How will the industry shape up by 2023 and what it means for Pharma & Nutraceutical companies in 2018 ?
As most of the organizations are focusing on quantum growth, they perform at the cost of health of their organization. This weakens competency and leadership of the organization which over a period of time, affects business performance. As on today not more than 1% of total revenue is spent on learning and development of people. This needs to be increased for better balance of Business Performance and Business Health.
It is an additional benefit at this moment for the companies as they are more focused on improving business performance. However, they get hooked when we talk about Business Health. Many entrepreneur-based organizations do not worry about Business Health.
2. How well is Interlink positioned to deliver effective Strategies for Improving Business Performance and Health of Pharma Companies ?
Track record of improving business performance of more than 40-50- clients and also Brand Performance of also more than 50 brands.
Oversight #1: As environment is changing and priorities are shifting, entrepreneurs feel they are not growing as much as they want. This is not a fault of employees as they are not ready for transition.
Oversight #2: They expect miracles in short time within 7-8 months.
Oversight #3: Internal organizations sometimes do not co-operate for building growth.
3. What is Interlink’s Value Proposition?
Process, rigor and eye on milestones achievements for building growth has been the hallmark for all business performance and health project.
4. How do we create value in our engagement?
While most of the industry players engage on two node fee structure, Interlink offers its clients milestones based payments. We use tools and technology to bring in transparency in all our engagements to that the client expectations and our deliverable match completely. We follow strong processes that in turns enhances the value of our client’s experiences.